Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …

The previous decade has seen a rapid increase in microglial studies on pain, with a unique
focus on microgliosis in the spinal cord after nerve injury and neuropathic pain. Numerous …

Astrocytes are critical for maintaining the homeostasis of the CNS. Increasing evidence
suggests that a number of neurological and neuropsychiatric disorders, including chronic …

Interactions between central glial cells and neurons in the pain circuitry are critical
contributors to the pathogenesis of chronic pain. In the central nervous system (CNS), two …

Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

Peripheral neuropathies are characterized by nerves damage and axonal loss, and they
could be classified in hereditary or acquired forms. Acquired peripheral neuropathies are …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect
experienced by cancer patients receiving treatment with paclitaxel. The voltage-gated …

Chemotherapy-induced peripheral neuropathic pain (CIPNP)—a severe adverse effect
observed in up to 80% of patients during treatment with antineoplastic drugs—limits the …